Skip to main content

Table 1 Clinical features of AML patients according to UGT1A1 genotypes

From: Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens

Clinical features Total (n = 726) UGT1A1*28 UGT1A1*6
*1/*1 (n = 579) *28/− (n = 147) P value *1/*1 (n = 493) *6/− (n = 233) P value
Age, years 41 ± 14 41 ± 14 41 ± 15 0.816 41 ± 14 42 ± 14 0.799
Male sex, n (%) 400 (55.1) 317 (54.7) 83 (56.5) 0.709 280 (56.8) 120 (51.5) 0.181
Smoking, n (%) 171(23.6) 141 (24.4) 30 (20.4) 0.314 125 (25.4) 46 (19.7) 0.096
Drinking, n (%) 108 (14.9) 91 (15.7) 17 (11.6) 0.206 69 (14.0) 39 (16.7) 0.332
FAB classification, n (%)
 M0 3 (0.4) 2 (0.3) 1 (0.7) 0.918 1 (0.2) 2 (0.9) 0.204
 M1 38 (5.2) 10 (5.2) 11 (7.5)   33 (6.7) 8 (3.4)  
 M2 372 (51.2) 298 (51.5) 74 (50.3)   258 (52.3) 114 (48.9)  
 M4 149 (20.5) 118 (20.4) 28 (19.0)   94 (19.1) 52 (23.3)  
 M5 146 (20.1) 117 (20.2) 29 (19.7)   97 (19.7) 49 (21.0)  
 M6 17 (2.3) 13 (2.2) 4 (2.7)   9 (1.8) 8 (3.4)  
 M7 1 (0.1) 1 (0.2)   1 (0.2)  
AML type, n (%)
 De novo AML 692 (95.3) 551 (95.2) 141 (95.9) 0.699 469 (95.1) 223 (95.7) 0.732
 Secondary AML 34 (4.7) 28 (4.8) 6 (4.1)   24 (4.9) 10 (4.7)  
Parameters at diagnosis
 WBC count, × 109/l 40.07 ± 62.15 39.54 ± 62.53 42.17 ± 60.80 0.650 40.70 ± 59.07 38.72 ± 68.37 0.691
 RBC count, × 1012/l 2.33 ± 1.64 2.26 ± 0.77 2.60 ± 3.33 0.232 2.39 ± 1.93 2.21 ± 0.73 0.173
 Hemoglobin, g/l 73.98 ± 21.68 73.64 ± 21.86 75.36 ± 20.99 0.395 74.61 ± 22.25 72.66 ± 20.44 0.261
 Platelets count, × 109/l 55.41 ± 64.40 54.70 ± 60.73 58.22 ± 77.45 0.559 53.90 ± 61.17 58.62 ± 70.80 0.360
 Neutrophil count, × 109/l 13.44 ± 33.00 13.51 ± 34.56 13.14 ± 26.04 0.905 13.98 ± 32.47 12.29 ± 34.23 0.525
 LDH, U/l 564.6 ± 725.2 561.2 ± 771.9 578.2 ± 501.1 0.806 566.4 ± 758.5 560.9 ± 651.7 0.926
 Bone marrow blasts, % 65.37 ± 20.88 64.94 ± 20.81 67.02 ± 21.12 0.291 65.98 ± 21.21 64.08 ± 20.15 0.267
Risk stratifications, n (%)
 Low risk 152 (20.9) 115 (19.9) 37 (25.2) 0.553 98 (19.9) 54 (23.2) 0.142
 Intermediate risk 330 (45.5) 267 (46.1) 63 (42.9)   230 (46.7) 100 (42.9)  
 High risk 140 (19.3) 114 (19.7) 26 (17.7)   102 (20.7) 38 (16.3)  
 Unknown 104 (14.3) 83(14.3) 21 (14.3)   63 (12.8) 41 (17.6)  
HSCT, n (%) 124 (17.1) 94 (16.2) 30 (20.4) 0.230 89 (18.1) 35 (15.0) 0.311
  1. *28/− or *6/− represents mutant homozygous and heterozygous of corresponding loci on UGT1A1
  2. Risk stratification based on NCCN guidelines version 1.2015 acute myeloid leukemia
  3. FAB Classification French–Britain–American Classification, HSCT hematopoietic stem cell transplantation, LDH lactate dehydrogenase, RBC red blood cell, WBC white blood cell
  4. P value was based on χ2 test for categorical variables and student’s t test for continuous variables